Pilot study to investigate the anti-inflammatory effects of caffeine in subjects with chronic obstructive pulmonary disease (COPD)

Completed

Conditions: chronic inflammation
chronic obstructive pulmonary disease (COPD)
10038716

Registration Number: NL-OMON31548

Lead Sponsor: Technologiestichting STW (NWO)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 12

Inclusion Criteria

Male subjects in an age of 40-70 years
BMI > 20 kg/m2 and < 30 kg/m2
Diastolic blood pressure (DBP)=60-90 mmHg, Systolic blood pressure (SBP)=100-150 mmHg
CRP-levels > 3mg/l
No acute and/or chronic inflammatory condition such as arthritis, arthrosis, chronic colitis, etc. during three months before entry of the study
No respiratory tract infection or exacerbation of COPD for at least 8 weeks prior to the start of the study
No change in treatment regime of the COPD subjects for at least 8 weeks prior to the start of the study
Normal constant dietary eating habits and a usual coffee consumption of at least 3 cups per day
Non-smokers and stopped smoking, respectively

Exclusion Criteria

Women
age < 40 years or > 70 years old
BMI <= 20 kg/m2 and >= 30 kg/m2
Diastolic blood pressure (DBP) < 60 or > 90 mmHg, systolic blood pressure (SBP) <100 or >150 mmHg
Acute and/or chronic inflammatory condition such as arthritis, arthrosis, chronic colitis, etc. during three months before entry of the study
Respiratory tract infection or exacerbation of COPD during the last 8 weeks prior to the start of the study
Change in treatment regime of the COPD subjects during the last 8 weeks prior to the start of the study
Irregular eating habits, usual coffee consumption of less than 3 cups per day and current smoker

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of the present study is to investigate the effects of a<br /><br>one-week daily supplementation of COPD patients with 2 x 250mg caffeine on<br /><br>biomarkers of systemic inflammation in blood such as C-reactive protein (CRP)<br /><br>and the cytokines TNF-a, IL-6, IL-8 and IL-10. </p><br>

Secondary Outcome Measures